

ASX RELEASE



ASX Code: ESE

22 January 2018

ESENSE & ATM SECURE APPROVALS TO COMMENCE INITIAL TERM OF OFFTAKE AGREEMENT

- The initial term of the Off-take Agreement with Advanced Technology Management Private Limited (ATM) announced on 23 October 2017 has now commenced
- Valued at a minimum of US\$540,000 to US\$600,000 within the first 12 months
- Approvals allow commencement of sales & distribution within Singapore

Life sciences company **eSense-Lab Ltd** ("**eSense**" or the "**Company**") (ASX: ESE) is pleased to announce that Singaporean strategic partner Advanced Technology Management Private Limited (**ATM**) has advised that it has obtained the necessary approvals for marketing, sales and distribution within Singapore as part of its Off-take Agreement ("**Agreement**") for sales distribution of eSense's product line. Marketing, sales and distribution activities are expected to commence immediately.

As per the Agreement announced on 23 October 2017, these approvals trigger the commencement of the initial 12-month term of the Agreement, commencing on 14 January 2017, during which, amongst other things, ATM must purchase a minimum quantity of eSense's products. ATM will pay a pre-determined price depending on the type of product or formulation, with the value of the Agreement based on the **minimum commitments being between US\$540,000 and US\$600,000** (depending on the type of products purchased).

Initial marketing activities will see ATM approach businesses in various sectors to formulate final products. Once developed, ATM and its customers will pursue clearance from respective country authorities where the customer (buyer) deems legally necessary.

Commenting on the milestone eSense CEO Haim Cohen said: *"I am very pleased that ATM has obtained the required approvals so that its work under this Agreement can now commence. Our Chief Technology Officer worked closely with the team at ATM to obtain the necessary approvals in an efficient and timely manner. This is a significant commercial order for our unique medical cannabis terpene profiles and we are looking forward to entering the rapidly growing and extensive Asian market. We thank ATM for the support the team there has shown thus far and will continue to work closely with them to expand eSense's product output."*

Now that ATM has the required Singaporean approvals, it can now seek approvals in other Asian countries.

The Agreement between ATM and eSense is binding and as such grants ATM exclusivity for distribution within Singapore. The Agreement will automatically renew for one-year terms unless either party provides the other with written notice at least 90 days prior to the expiry of the term that it elects not to renew the Agreement.

FOR FURTHER INFORMATION:

Haim Cohen
CEO & Director
haim@esense-lab.com

[Investor/media relations](#)
Matthew Wright
+61 451 896 420
matt@nwrcommunications.com.au

About ATM

ATM is a leader in cross-border business development, advising in setting up and managing business centres in Asia. ATM has been consistently owned and managed by the same team since establishment in 2007 and has a track record of providing independent advice to diverse corporate and technology sponsor clients from North America, Europe and Asia.

ATM has assisted numerous multinational corporations and technology companies to increase strategic value by bringing to bear knowledge and expertise on transactions and alliances between companies in Asia and the West. ATM works across many sectors and has strong regional experience in Asia, with particular expertise in the, Healthcare & Life Sciences, Technology, Chemicals Industrials and Services sectors.

About eSense-Lab

eSense-Lab Ltd (ASX: ESE) is a life sciences company specialising in the commercialisation of the phytochemical profiling of plants. The Company combines genetics, mRNA, protein expression and phytochemical profiles to generate a comprehensive model of rare or high value plants. eSense-Lab can then use this model to 'reverse engineer' a terpene profile, which is a naturally occurring formulation of different individual terpenes which together account for many of the plant's health and medical benefits, whilst also exactly replicating the flavour, fragrance and other desired characteristics of the targeted plant, at a more sustainable and cheaper cost

To learn more about eSense-Lab, visit www.esense-lab.com